Form 4: AN2 Therapeutics Director Acquires Shares as Compensation

Director Gilbert Lynn Marks acquired 8,972 shares of AN2 Therapeutics stock as part of non-employee director compensation.

Summary

• Gilbert Lynn Marks, a director at AN2 Therapeutics, acquired 8,972 shares of common stock on December 19, 2024.
• These shares were issued as compensation in lieu of cash under the company's non-employee director compensation policy.
• The shares were acquired at a price of $0 and vest immediately.
• Following this transaction, Mr. Marks directly owns 31,802 shares of AN2 Therapeutics stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director demonstrates alignment of interests with shareholders.
• The use of stock as compensation can conserve company cash.

Industry Context

This type of transaction is common for directors of publicly traded companies, aligning their interests with shareholders through equity ownership.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation for directors to conserve cash and align interests.
• The immediate vesting of shares is a common practice for director compensation.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning his interests with shareholders.
• The use of stock for compensation can be seen positively by shareholders as it reduces cash outflow.

Key Dates

Keywords

AN2 Therapeutics, Director, Stock Acquisition, Compensation, Gilbert Lynn Marks, ANTX, Share Ownership